Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

Fexingo
  • 0.0 (0)
  • Business
  • Updated Daily

Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure? #Biotech #Lifesciences #DrugDiscovery #FDAApprovals #ClinicalTrials #Startups #VentureCapital #Pharma #Genomics #CRISPR #Therapeutics #RegulatoryScience #Patents #Investment #Business #FexingoBusiness #BusinessPodcast #Technology Keep every episode free: buymeacoffee.com/fexingo

  1. 12h ago

    How Biotech Startups Use Spatial Transcriptomics

    This episode of Biotech Business explores how startups are using spatial transcriptomics to map gene activity directly inside tissue, revealing the cellular geography of disease. Lucas and Luna break down the technology — from imaging-based methods like MERFISH to sequencing-based platforms — and discuss how it's reshaping drug discovery, from identifying novel targets to stratifying patients for clinical trials. They highlight a fresh, recent case: a startup using spatial transcriptomics to uncover a new cellular neighborhood in early-stage breast cancer that correlates with immunotherapy resistance, potentially opening a new biomarker avenue. They also touch on the computational hurdles — massive datasets, integration with single-cell data — and whether spatial data is ready for the clinic. If you're curious about how spatial biology is accelerating drug development, this episode delivers a clear, concrete introduction. #SpatialTranscriptomics #BiotechStartup #DrugDiscovery #PrecisionMedicine #Biomarker #TumorMicroenvironment #MERFISH #Visium #SpatialBiology #Genomics #Immunotherapy #CancerResearch #ClinicalTrials #Business #Technology #FexingoBusiness #BusinessPodcast #BiotechBusiness Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Use Spatial Transcriptomics

  2. 1d ago

    How Biotech Startups Use CRISPR Screens to Find New Drug Targets

    In episode 161, Lucas and Luna dive into the world of CRISPR screens — a high-throughput method that lets biotech startups knock out thousands of genes at once to uncover which ones drive disease. They break down the difference between pooled and arrayed screens, walk through a real-world example from a startup hunting for combination therapies in ovarian cancer, and discuss the surprising finding that many new targets are genes we already knew about but never thought to drug. With a nod to the latest CRISPR screening startups and the workhorse Cas9 enzyme, this episode explains how systematic gene knockout is reshaping early-stage drug discovery. Plus, they talk about the challenge of off-target effects and what the future holds for CRISPR screens combined with single-cell readouts. If you've ever wondered how biotech companies decide which genes to target, this episode gives you the inside track. #CRISPR #CRISPRScreens #DrugDiscovery #GeneEditing #BiotechStartups #Genomics #CancerResearch #OvarianCancer #CombinationTherapies #Cas9 #HighThroughputScreening #PooledScreens #ArrayedScreens #OffTargetEffects #SingleCell #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Use CRISPR Screens to Find New Drug Targets

  3. 2d ago

    How Biotech Startups Use Patient Registries

    In this episode of Biotech Business with Fexingo, Lucas and Luna dive into the world of patient registries — organized systems that collect real-world data from patients with specific conditions. They explore how startups are leveraging these registries to accelerate drug development, improve trial design, and even support regulatory approvals. Using the example of a rare disease registry, they break down the practical steps, data quality challenges, and the shift toward patient-reported outcomes. If you're in biotech, pharma, or just curious about how real-world evidence is reshaping the industry, this episode offers a clear, grounded look at an underappreciated tool. Tune in for insights on how patient registries are becoming a cornerstone of modern drug discovery. #PatientRegistries #RealWorldData #DrugDiscovery #BiotechStartups #RareDisease #ClinicalTrials #PatientCentricity #FDAApproval #HealthTech #DigitalHealth #LifeSciences #DataScience #BiotechBusiness #FexingoBusiness #BusinessPodcast #Podcast #Innovation #VentureCapital Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Use Patient Registries

  4. 3d ago

    How Biotech Startups Use AI to Repurpose Existing Drugs

    In this episode of Biotech Business, Lucas and Luna explore the emerging field of AI-powered drug repurposing. They discuss how startups like Healx and Recursion are using machine learning to find new uses for existing drugs, dramatically cutting the time and cost of bringing treatments to patients. The conversation centers on a recent success story: a repurposed drug for a rare genetic disorder that moved from computer prediction to Phase II trials in under two years. Lucas explains the technology behind these platforms, including graph neural networks and knowledge graphs, and contrasts the AI approach with traditional repurposing methods. Luna raises questions about regulatory pathways and the risks of relying on black-box models. The episode also touches on the broader trend of pharma companies partnering with AI startups, and what this means for the future of drug development. Tune in to understand how AI is turning the drug discovery process on its head. #BiotechBusiness #AI #DrugRepurposing #Healx #Recursion #RareDisease #MachineLearning #DrugDiscovery #Pharma #FDA #Genetics #Startups #Technology #Business #FexingoBusiness #BusinessPodcast #PrecisionMedicine #ClinicalTrials Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Use AI to Repurpose Existing Drugs

  5. 4d ago

    How Biotech Startups Use Liquid Biopsies to Find Cancer Early

    Liquid biopsies are quietly transforming how we detect and monitor cancer — and biotech startups are at the center of it. In this episode, Lucas and Luna dig into the science and the business. They trace how a simple blood draw can catch tumor DNA months before symptoms appear, then follow a specific startup that's using methylation patterns to spot multiple cancer types at once. They break down why the economics are finally working: the cost per test has dropped from thousands to a few hundred dollars, and the FDA has approved several for clinical use. They also talk about the limits — why liquid biopsies aren't replacing tissue biopsies just yet, and where the technology still struggles with early-stage tumors. With the market projected to hit double-digit billions by 2030, startups are racing to stand out. Lucas and Luna explore what separates the winners from the also-rans: data moats, reimbursement strategy, and partnerships with health systems. A conversation for anyone curious about how a drop of blood could change the future of cancer care. #LiquidBiopsy #CancerDetection #EarlyDetection #BiotechStartup #ctDNA #Methylation #FDAApproval #PrecisionMedicine #Oncology #GuardantHealth #Grail #BiomarkerDiscovery #HealthcareInnovation #ClinicalTrials #Reimbursement #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Use Liquid Biopsies to Find Cancer Early

  6. 5d ago

    How Biotech Startups Are Using Digital Twins

    Digital twins — virtual replicas of physical systems — are moving from manufacturing and aerospace into biotech. In this episode, Lucas and Luna explore how startups are building digital twins of clinical trials, manufacturing lines, and even individual patients to cut costs and speed up development. They look at how a mid-stage biotech company used a digital twin of a Phase 3 trial to simulate different enrollment scenarios and adjust their strategy before spending a dime. They also discuss the challenges: data quality, regulatory acceptance, and the risk of over-reliance on models. If you're in biotech or just curious about the intersection of software and drug development, this episode gives you a clear picture of a tool that's quietly changing the industry. #DigitalTwins #Biotech #DrugDevelopment #ClinicalTrials #Simulation #Startups #Manufacturing #RegulatoryAffairs #FDA #MachineLearning #Pharma #Business #Technology #FexingoBusiness #BusinessPodcast #LifeSciences #Innovation #AI Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Are Using Digital Twins

  7. 6d ago

    How Biotech Startups Use Antibody-Drug Conjugates

    In this episode of Biotech Business with Fexingo, Lucas and Luna explore how biotech startups are leveraging antibody-drug conjugates, or ADCs, to target cancer cells with precision. They break down the science behind ADCs, the business case for startups entering this space, and the challenges of manufacturing and safety. With real examples from the industry, they discuss why ADCs are becoming a hot area for investment and what it means for the future of oncology. Tune in to understand the mechanics of ADCs, the regulatory landscape, and how startups are positioning themselves in a competitive market. This episode is a must-listen for anyone interested in the intersection of biotech innovation and business strategy. #AntibodyDrugConjugates #BiotechStartups #CancerTherapy #DrugDelivery #Oncology #PrecisionMedicine #BiotechBusiness #Business #Technology #FexingoBusiness #BusinessPodcast #LifeSciences #DrugDiscovery #FDAApprovals #HealthcareInnovation #BiotechInvesting #TargetedTherapy #StartupEcosystem Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Use Antibody-Drug Conjugates

  8. Aug 14

    How Biotech Startups Are Using In Vivo Gene Editing

    In episode 155, Lucas and Luna explore the shift from ex vivo to in vivo gene editing, a frontier that could make one-time genetic therapies accessible beyond rare diseases. They break down the science behind lipid nanoparticle and viral vector delivery, the challenge of targeting the right cells, and the recent momentum signaled by FDA guidance. The conversation zooms in on a notable 2025 clinical data readout for a base-editing candidate for a cholesterol disorder, and what it means for the startup playbook. They also discuss the economics of in vivo editing versus traditional protein therapies, and why investors are paying attention to delivery platforms. A quick look at the regulatory landscape and the implications for patients rounds out the episode, with no fluff—just the specifics that matter for anyone following biotech innovation. #InVivoGeneEditing #BiotechStartups #GeneTherapy #BaseEditing #DrugDelivery #CellSpecificTargeting #FDA #ClinicalTrials #CholesterolDrug #BiotechBusiness #ScienceAndTech #LifeSciences #BiotechInvesting #FexingoBusiness #BusinessPodcast #BiotechPodcast #GeneEditing #BiotechTrends Keep every episode free: buymeacoffee.com/fexingo

    How Biotech Startups Are Using In Vivo Gene Editing
See All (162)

About

Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure? #Biotech #Lifesciences #DrugDiscovery #FDAApprovals #ClinicalTrials #Startups #VentureCapital #Pharma #Genomics #CRISPR #Therapeutics #RegulatoryScience #Patents #Investment #Business #FexingoBusiness #BusinessPodcast #Technology Keep every episode free: buymeacoffee.com/fexingo

Information